LMAN2 is a robust prognostic biomarker that promotes breast tumor growth and anthracycline resistance by enabling SCD-dependent lipid desaturation and Therapeutic targeting of the LMAN2/SCD axis represents a promising strategy to overcome chemoresistance in breast cancer.
Chang-Jiao Yan, Feng-Qiang Cui, Chu-Tuo Liu et al.· Breast Cancer Research· 0 citations
Abstract Background Thyroid cancer incidence is rising worldwide, yet comprehensive longitudinal data linking contemporary demographic, pathological, and surgical trends to recurrence risk remain scarce. Methods A retrospective analysis was performed on 9504 thyroid cancer patients from 2008 to 2023. Based on the year...
Sijin Guo, Yang Wang, Changjiao Yan et al.· Journal of the Endocrine Soc...· 0 citations
BACKGROUND
m5C modification plays a vital role in the progression of human cancers, including breast cancer (BC), but the function of NOP2/Sun RNA methyltransferase 2 (NSUN2), an RNA m5C modification enzyme, remains largely unclear.
METHODS
qRT-PCR, western blot and IHC assays were carried out to determine the expres...
Xin Li, Changjiao Yan, Jun Yi et al.· Cell Division· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.